AI pharma trend sweeps to create a "new normal" for drug research and development

The current AI pharmaceutical projects under research are widely distributed in cancer, respiratory system, anti-infection, mental disorders, immune system, ophthalmology, cardiovascular, digestive system, endocrine system, drug side effects research and other fields, among which cancer and mental disease treatment fields AI pharmaceutical cooperation projects accounted for the highest proportion, 29% and 27%, respectively, followed by cardiovascular disease treatment, accounting for 1

With the improvement of AI application maturity, the penetration rate of AI technology in the pharmaceutical field will continue to increase in the future, and AI pharmaceuticals may become the mainstream way of innovative drug research and developme.

According to the three main entities, the application of AI pharmaceuticals in the AI ​​pharmaceutical market can be traced back to the 198
After decades of development, with the continuous maturity of AI technology and the increasing confidence of the capital market in the industry, the current AI pharmaceuticals has Entering the period of rapid developmentAt present, there are three main types of entrants in the domestic and foreign AI pharmaceutical market, namely large pharmaceutical companies, AI pharmaceutical start-ups and leading Internet compani.

Large pharmaceutical companies are further divided into traditional pharmaceutical companies and CRO compani.

According to data from Deep Pharma Intelligence, as of the first quarter of 2022, there were more than 56 large pharmaceutical companies participating in AI drug R&D worldwide, including more than 36 traditional pharmaceutical companies and 20 CRO companies; 31; more than 495 AI pharmaceutical start-u.

Large pharmaceutical companiesAs domestic and foreign large pharmaceutical companies gradually realize the application value of AI technology in the pharmaceutical field, more and more traditional pharmaceutical companies and CRO companies are pouring into the AI ​​pharmaceutical field, and the number of AI pharmaceutical projects worldwide is increasing year by ye.

Among them, large pharmaceutical companies are mainly foreign-funded multinational companies, and local pharmaceutical companies are relatively cautious in this fie.

There are three main ways for large pharmaceutical companies to enter the market: one is to build their own AI R&D teams internally, such as Novartis and GlaxoSmithKline, which were earlier in the industry to set up their own AI departments; the other is to invest in external AI pharmaceutical start-ups Mergers and acquisitions, such as Fosun Pharma this year announced that it will invest in equity while cooperating with Insilicon; the third is to cooperate with Internet giants or AI startups, such as Chia Tai Tianqing obtained a brand new compound screening through cooperation with Alibaba Cloud Approach, WuXi AppTec and Schrdinger jointly established Faxian Therapeutics to accelerate new drug discovery,e.

 AI pharma startup
As the core subject of the market, AI pharmaceutical start-ups usually use their own AI technology advantages to enter one or more links in the pharmaceutical scene, and generally enter the market in the form of cooperation with large pharmaceutical compani.

The commercial capabilities of AI pharmaceutical start-ups are mainly reflected in two aspects: first, the ability of AI technology services, the more obvious the technical advantages, the more favored large-scale enterprise partners; After the company, it will further expand its leading edge in the indust.

In recent years, more and more traditional pharmaceutical companies and CRO companies with a layout in the field of AI pharmaceuticals have chosen to cooperate with leading AI pharmaceutical start-ups, aiming to save R&D costs to the greatest extent and use the advantages of both parties to improve the efficiency of new drug R&.

For example, in early 2022, Fosun Pharma, a large local pharmaceutical company, and Insilicon, a well-known AI pharmaceutical company, have reached a strategic cooperati.

They will use AI to drive drug research and development for four designated targets, and jointly develop and cooperate with Insilicon's QPCTL proje.

The first payment of the project As high as 13 million US dollars, setting a new domestic transaction record in this fie.

In recent years, Internetgiants at home and abroad have successively deployed in the field of AI pharmaceutica.

The main ways to enter the market are to invest in AI start-ups, independently develop and establish AI pharmaceutical platforms, and cooperate with external institutions to develop AI pharmaceutical projec.

Among local Internet leading companies, Tencent, Huawei, and Baidu have all developed AI pharmaceutical platforms; Alibaba Cloud is cooperating with the Global Health Drug R&D Center to develop AI drug R&D and big data platfor.

The research of leading Internet companies in the field of AI pharmaceuticals mainly focuses on the research and development of new dru.

Compared with AI pharmaceutical start-ups and large pharmaceutical companies, they have unique advantages in the fields of AI technology such as databases and cloud computing necessary for the AI ​​pharmaceutical fie.

It is expected that the Internet giants will be more active and penetrated in the field of AI pharmaceuticals in the future, and they will continue to promote the development of this field by using their advantages in algorithms and computing pow.
 The potential space of AI pharmacy in China has gradually opened up.